Xenetic Biosciences, Inc. - Common Stock (NQ:XBIO)

2.050 -0.070 (-3.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xenetic Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 30, 2022

Via Benzinga

Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session ↗

November 16, 2022

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.

Via Benzinga

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

November 16, 2022

Via ACCESSWIRE

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

November 10, 2022

Via ACCESSWIRE

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

October 11, 2022

Via ACCESSWIRE

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

October 04, 2022

Via ACCESSWIRE

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 07, 2022

Via ACCESSWIRE

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

August 02, 2022

Via ACCESSWIRE

Stocks That Hit 52-Week Lows On Friday ↗

October 28, 2022

During Friday, 125 stocks hit new 52-week lows.

Via Benzinga

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

July 07, 2022

FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology...

From Xenetic Biosciences, Inc.

Via AccessWire

Topics Intellectual Property

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

June 02, 2022

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -

From JTC Team, LLC

Via AccessWire

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

June 02, 2022

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET

From Xenetic Biosciences, Inc.

Via AccessWire

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...

From Xenetic Biosciences, Inc.

Via AccessWire

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

May 12, 2022

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential...

From Xenetic Biosciences, Inc.

Via AccessWire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 04, 2022

Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 28, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 28, 2022

Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday!

Via InvestorPlace

74 Biggest Movers From Yesterday ↗

April 29, 2022

Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric...

Via Benzinga

28 Stocks Moving in Thursday's Pre-Market Session ↗

April 28, 2022

Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust Stamp recently posted Q4 net sales of $2.1...

Via Benzinga

48 Stocks Moving In Thursday's Mid-Day Session ↗

April 28, 2022

Gainers T Stamp Inc. (NASDAQ: IDAI) shares jumped 201% to $6.33. Trust Stamp reported the launch of its Biometric Multi-Factor Authentication (Biometric MFATM) solution. Statera...

Via Benzinga

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

April 27, 2022

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the...

From Xenetic Biosciences, Inc.

Via AccessWire

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

March 23, 2022

- XCARTTM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA /...

From Xenetic Biosciences, Inc.

Via AccessWire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 08, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 23, 2022

Gainers SCYNEXIS (NASDAQ:SCYX) shares inc...

Via Benzinga

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

January 12, 2022

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...

From JTC Team, LLC

Via AccessWire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 11, 2022

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 22, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (...

Via Benzinga

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 12, 2021

- Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies - Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million...

From Xenetic Biosciences, Inc.

Via AccessWire

Topics Intellectual Property Regulatory Compliance

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.